Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

References

• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76. doi:10.1056/NEJMoa072113. PMID:18160686.
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47. doi:10.1200/JCO.2008.21.6457. PMID:20498403.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60. doi:10.1200/JCO.2010.28.0982. PMID:21383283.
   PubMed Web of Science ®Google Scholar
• Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): Primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17:1230–9. doi:10.1016/S1470-2045(16)30154-1. PMID:27501767.
   PubMed Web of Science ®Google Scholar
• Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017;70:146–55. doi:10.1016/j.ejca.2016.09.024. PMID:27817944.
   PubMed Web of Science ®Google Scholar
• Masuda N, Takahashi M, Nakagami K, Okumura Y, Nakayama T, Sato N, Kanatani K, Tajima K, Kashiwaba M, et al. First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: Subgroup results from the randomized Phase III MERiDiAN trial. Jpn J Clin Oncol. 2017;47:385–92. doi:10.1093/jjco/hyx001. PMID:28158579.
   PubMed Web of Science ®Google Scholar
• Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, et al. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. J Cell Physiol. 2017;232:1571–78. doi:10.1002/jcp.25685. PMID:27861874.
   PubMed Web of Science ®Google Scholar
• Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, et al. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. Sci Rep. 2017;7:10597. doi:10.1038/s41598-017-10061-2. PMID:28878375.
   PubMed Web of Science ®Google Scholar
• Barba M, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, et al. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer. 2017;17:101. doi:10.1186/s12885-016-3045-z. PMID:28166748.
   PubMed Web of Science ®Google Scholar
• Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Di Filippo S, et al. Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. J Cell Physiol. 2016;231:2541–7. doi:10.1002/jcp.25432. PMID:27187274.
   PubMed Web of Science ®Google Scholar
• Vici P, Pizzuti L, Di Lauro L, Conti L, Mandoj C, Antenucci A, Digiesi G, Sergi D, Amodio A, Marchetti P, et al. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. J Cancer. 2016;7:516–22. doi:10.7150/jca.13578. PMID:26958087.
   PubMed Web of Science ®Google Scholar
• D'Aiuto M, Chirico A, De Riggi MA, Frasci G, De Laurentiis M, Di Bonito M, Vici P, Pizzuti L, Sergi D, Maugeri-Saccà M, et al. Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 years or younger: Evidence from a historic cohort. Cancer Biol Ther. 2016;17:470–6. doi:10.1080/15384047.2016.1156265. PMID:26934127.
   PubMed Web of Science ®Google Scholar
• Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, et al. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. J Cell Physiol. 2016;231:986–91. doi:10.1002/jcp.25213. PMID:26449308.
   PubMed Web of Science ®Google Scholar
• Vici P, Crispo A, Giordano A, Di Lauro L, Sperati F, Terrenato I, Pizzuti L, Sergi D, Mottolese M, Botti C, et al. Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. J Cell Physiol. 2015;230:1708–12. doi:10.1002/jcp.24891. PMID:25510909.
   PubMed Web of Science ®Google Scholar
• Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, et al. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget. 2014;5:10382–92. doi:10.18632/oncotarget.2060. PMID:25071015.
   PubMed Web of Science ®Google Scholar
• http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi.
   Google Scholar
• Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. Cancer Epidemiol Biomarkers Prev. 2013;22:1862–67. doi:10.1158/1055-9965.EPI-13-0595. PMID:23945199.
   PubMed Web of Science ®Google Scholar
• Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324–30. doi:10.1200/JCO.2007.14.2471. PMID:18612148.
   PubMed Web of Science ®Google Scholar
• Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36:237–49. doi:10.1053/j.seminoncol.2009.03.001. PMID:19460581.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Soerjomataram I. Obesity as an Avoidable Cause of Cancer (Attributable Risks). Recent Results Cancer Res. 2016;208:243–256. doi:10.1007/978-3-319-42542-9_13. PMID:27909911.
   PubMedGoogle Scholar
• Bittoni MA, Fisher JL, Fowler JM, Maxwell GL, Paskett ED. Assessment of the effects of severe obesity and lifestyle risk factors on stage of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:76–81. doi:10.1158/1055-9965.EPI-12-0843. PMID:23118146.
   PubMed Web of Science ®Google Scholar
• Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, et al. Obesity, body size, and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control. 2002;13:741–51. doi:10.1023/A:1020239211145. PMID:12420953.
   PubMed Web of Science ®Google Scholar
• Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist 2012. 17:1014–26.
   Google Scholar